Sign Out
For IM Injection: Reconstitute with 2.4 mL of sterile water for injection.
For IV Infusion: Reconstitute with 10 mL of sterile water for injection & added to compatible IV solution (5% Dextrose, 10% Dextrose, 0.9% NaCl Injection & 5% Dextrose and 0.9% Sodium Chloride Injection for further dilution). Cefepime with Tazobactam preferably is administered by IV infusion but also can be given by deep IM injection when indicated.
Cefepime with Tazobactam should be administered intravenously over 30 minutes. The recommended dosage are expressed as Cefepime as per the following.
Intra-abdominal Infections: The usual adult dosage is 2 g given IV every 12 hours for 7-10 days.
Pneumonia: For the treatment of moderate to severe pneumonia caused by Streptococcus pneumoniae (including those with concurrent bacteremia), the usual adult dosage is 1-2 g given IV every 12 hours for 10 days.
For initial therapy of hospital-acquired pneumonia, ventilator-associated pneumonia or health-care associated pneumonia, some clinicians recommend that adults receive dosage of 1-2 g every 8-12 hours.
Skin and Skin Structure Infections: For the treatment of moderate to severe uncomplicated skin and skin structure infections caused by Staphylococcus aureus or Streptococcus pyogenes, the usual adult dosage is 2 g IV every 12 hours for 10 days.
Urinary Tract Infections: For the treatment of mild to moderate uncomplicated or complicated urinary tract infections (including those associated with pyelonephritis and/or with concurrent bacteremia), the usual adult dosage of cefepime is 500 mg-1 g administered IV or IM every 12 hours for 7-10 days.
For the treatment of severe uncomplicated or complicated urinary tract infections (including those associated with pyelonephritis and/or concurrent bacteremia), adults should received 2 g IV every 12 hours for 10 days.
Empiric Therapy in Febrile Neutropenic Patients: For empiric anti-infective therapy in febrile neutropenic patients, adults should receive a dosage of 2 g IV every 8 hours for 7 days or until neutropenia resolves. The need for continued anti-infective therapy in patients whose fever resolves but who remain neutropenic for longer than 7 days should be frequently re-evaluated.
Paediatric Patients (2 months up to 16 years): The maximum dose for paediatric patients should not exceed the recommended adult dose. The usual recommended dosage in paediatric patients up to 40 kg in weight for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg/kg/dose, administered every 12 hours (50 mg/kg/dose, every 8 hours for febrile neutropenic patients), for durations as given previously.
Renal Impairment: Dosage adjustments necessary in patients with CLcr=60 mL/minute.
Adults with Clcr=60 mL/minute (not undergoing hemodialysis): Give an initial dose using usually recommended adult dosage followed by maintenance dosage based on Clcr. (See Tables 1 and 2.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/imageAdults undergoing hemodialysis: 1 g on the first day of treatment followed by 500 mg every 24 hours for treatment of infections or 1 g on the first day followed by 1 g every 24 hours for empiric therapy in febrile neutropenic patients. Administer the dose at the same time each day (given at completion of procedure on hemodialysis days).
Adults undergoing CAPD: Give usually recommended dose once every 48 hours.
Paediatric patients with renal impairment: Dosage adjustments required proportional to those recommended for adults.
Hepatic Impairment: Dosage adjustments not required.
